AIM2CERV: A Phase 3 Trial for Cervical Cancer

Description: Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center gives an overview of his presentation, AIM2CERV: Global Phase 3 Trial of Advaxis’ Axalimogene Filolisbac for Cervical Cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Shared By : AnnualMeeting2017
Posted on : 06/02/17
Added : 2 years ago
Category : Cervical Cancer